Vedanta Biosciences granted US patent

Patent broadly covers pharmaceutical compositions for microbiome therapeutics based on bacterial consortia.

The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta. Dr Honda’s work provides an avenue for the treatment of a variety of diseases including immune and infectious diseases employing bacterial strains belonging to Clostridium clusters IV and/or XIVa. Clostridium bacteria include a variety of spore-forming species that can abundantly colonize the gut.

“We believe this issuance puts Vedanta in an IP leadership position in the microbiome field,” said Bernat Olle, Chief Executive Officer of Vedanta. “The patent has broad, fundamental claims that we believe will be important for the commercialization of microbiome therapeutics based on bacterial consortia. We intend to continue to build value from our IP estate through our internal programs as well as alliances with pharmaceutical partners.”